Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 18.89% is in line with its 5-year average of 20.56%, near the low end of its 5-year range (15.54%–28.34%).
11.41% above its 12-month average of 16.95%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
18.89%
RETURN ON EQUITY (ROE) AVG TTM
16.95%
RETURN ON EQUITY (ROE) AVG 3Y
19.08%
RETURN ON EQUITY (ROE) AVG 5Y
20.56%
RETURN ON EQUITY (ROE) AVG 10Y
17.04%
RETURN ON EQUITY (ROE) AVG 15Y
15.39%
RETURN ON EQUITY (ROE) AVG 20Y
14.62%
CURRENT VS TTM AVG
+11.41%
CURRENT VS 3Y AVG
-1.01%
CURRENT VS 5Y AVG
-8.11%
CURRENT VS 10Y AVG
+10.83%
CURRENT VS 15Y AVG
+22.77%
CURRENT VS 20Y AVG
+29.17%
SECTOR MEDIAN · HEALTHCARE
13.38%
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+41.18%
vs the sector median at left
West Pharmaceutical Services, Inc.
Market Cap
$24.73B
Return on Equity (ROE)
18.89%
TTM Avg
16.95%
3Y Avg
19.08%
5Y Avg
20.56%
Market Cap
$24.54B
Return on Equity (ROE)
25.41%
TTM Avg
12.92%
3Y Avg
11.29%
5Y Avg
9.83%
Market Cap
$24.03B
Return on Equity (ROE)
-46.61%
TTM Avg
-32.64%
3Y Avg
-13.90%
5Y Avg
0.25%
Market Cap
$23.31B
Return on Equity (ROE)
-6.79%
TTM Avg
-4.55%
3Y Avg
10.63%
5Y Avg
21.70%
Market Cap
$26.21B
Return on Equity (ROE)
14.13%
TTM Avg
13.34%
3Y Avg
14.07%
5Y Avg
18.07%
Market Cap
$26.44B
Return on Equity (ROE)
11.65%
TTM Avg
9.71%
3Y Avg
9.35%
5Y Avg
12.84%
Market Cap
$21.88B
Return on Equity (ROE)
20.48%
TTM Avg
18.68%
3Y Avg
17.25%
5Y Avg
16.03%
Market Cap
$29.04B
Return on Equity (ROE)
7062.40%
TTM Avg
-2178.82%
3Y Avg
-341.14%
5Y Avg
-117.12%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| West Pharmaceutical Services, Inc. (WST) | $24.73B | 18.89% | 16.95% | 19.08% | 20.56% |
| Incyte Corporation (INCY)vs › | $24.54B | 25.41% | 12.92% | 11.29% | 9.83% |
| Moderna, Inc. (MRNA)vs › | $24.03B | -46.61% | -32.64% | -13.90% | 0.25% |
| BioNTech SE (BNTX)vs › | $23.31B | -6.79% | -4.55% | 10.63% | 21.70% |
| Quest Diagnostics Incorporated (DGX)vs › | $26.21B | 14.13% | 13.34% | 14.07% | 18.07% |
| STERIS plc (STE)vs › | $23.22B | 8.38% | 10.12% | 7.00% | 7.00% |
| Labcorp Holdings Inc. (LH)vs › | $26.44B | 11.65% | 9.71% | 9.35% | 12.84% |
| United Therapeutics Corporation (UTHR)vs › | $21.88B | 20.48% | 18.68% | 17.25% | 16.03% |
| Mettler-Toledo International Inc. (MTD)vs › | $29.04B | 7062.40% | -2178.82% | -341.14% | -117.12% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $29.60B | 59.67% | -187.43% | 134.89% | 51.69% |
ROE
18.9%
ROA
13.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 15.54% |
| 2024-12-31 | 18.37% |
| 2023-12-31 | 20.60% |
| 2022-12-31 | 21.82% |
| 2021-12-31 | 28.34% |
| 2020-12-31 | 18.67% |
| 2019-12-31 | 15.36% |
| 2018-12-31 | 14.82% |
| 2017-12-31 | 11.77% |
| 2016-12-31 | 12.85% |
| 2015-12-31 | 9.34% |
| 2014-12-31 | 13.28% |
| 2013-12-31 | 12.39% |
| 2012-12-31 | 11.07% |
| 2011-12-31 | 11.53% |
| 2010-12-31 | 10.44% |
| 2009-12-31 | 12.54% |
| 2008-12-31 | 17.66% |
| 2007-12-31 | 14.57% |
| 2006-12-31 | 16.19% |
| 2005-12-31 | 13.67% |
| 2004-12-31 | 6.44% |
| 2003-12-31 | 12.38% |
| 2002-12-31 | 9.13% |
| 2001-12-31 | -2.94% |
| 2000-12-31 | 0.78% |
| 1999-12-31 | 16.74% |
| 1998-12-31 | 2.91% |
| 1997-12-31 | 15.99% |
| 1996-12-31 | 6.51% |
